Literature DB >> 35859218

Fusobacterium nucleatum load in MSI colorectal cancer subtypes.

Tomoyuki Ono1, Tatsuro Yamaguchi2,3,4, Misato Takao1, Ekumi Kojika5,6, Takeru Iijima5,6, Shin-Ichiro Horiguchi7.   

Abstract

BACKGROUND: Fusobacterium nucleatum (F. nucleatum) infection may lead to colorectal cancer (CRC) development in the context of microsatellite instability (MSI). To date, however, the relationship between F. nucleatum load and MSI CRC subtypes has not been clarified.
METHODS: One hundred seventy-nine consecutive patients with CRC were enrolled in the present study. In 94 patients with MSI CRC, 32 had hereditary MSI CRC from Lynch syndrome, 62 had sporadic MSI CRC, while the remaining 85 had microsatellite stable (MSS) CRC. The association of the F. nucleatum load with each CRC subtype and the patients' clinicopathological characteristics was examined.
RESULTS: Of the 179 patients with CRC, 158 (88.3%) were F. nucleatum-positive. A high F. nucleatum load was found in 84.4% (27/32), 96.8% (60/62), and 83.5% (71/85) of the patients with hereditary MSI CRC, sporadic MSI CRC, and MSS CRC, respectively (P = 0.024). In terms of clinicopathological features, a high F. nucleatum load was significantly associated with female, right-sided CRC, BRAF V600E, CpG island methylator phenotype-positive CRC, and MSI CRC (P = 0.008, P = 0.015, P = 0.007, P = 0.006, and P < 0.001, respectively). However, the clinicopathological characteristics did not differ significantly by F. nucleatum load between hereditary and sporadic MSI CRCs without tumor depth.
CONCLUSIONS: The F. nucleatum load was higher in hereditary MSI CRC than in MSS CRC as well as sporadic MSI CRC. These findings may contribute to preventing CRC in hereditary MSI CRC through appropriate intervention.
© 2022. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.

Entities:  

Keywords:  Fusobacterium nucleatum; Lynch syndrome; MSI-H

Year:  2022        PMID: 35859218     DOI: 10.1007/s10147-022-02218-5

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.850


  1 in total

1.  First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.

Authors:  Heinz-Josef Lenz; Eric Van Cutsem; Maria Luisa Limon; Ka Yeung Mark Wong; Alain Hendlisz; Massimo Aglietta; Pilar García-Alfonso; Bart Neyns; Gabriele Luppi; Dana B Cardin; Tomislav Dragovich; Usman Shah; Sandzhar Abdullaev; Joseph Gricar; Jean-Marie Ledeine; Michael James Overman; Sara Lonardi
Journal:  J Clin Oncol       Date:  2021-10-12       Impact factor: 44.544

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.